Blog

BROOKLYN, NY / ACCESS Newswire / August 13, 2025 / IEH Corporation (OTC:IEHC) yesterday filed with the Securities and Exchange Commission (SEC) its quarterly report on Form 10-Q for the 1^st fiscal quarter ended June 30, 2025.

Highlights include:

• 11% Decrease in Revenue as compared to first quarter of Fiscal Year 2025

• $755,306 loss in Operating Income

• Cash 43% higher than first quarter of Fiscal Year 2025

• Backlog increase of 25% since beginning of Fiscal Year 2026

• Over $2.5 million in orders supporting missile defense programs booked in recent weeks

For the quarter ended June 30, 2025, IEH had revenues of $6,308,155 as compared to $7,104,977 for the quarter ended June 30, 2024 reflecting an 11% decrease; an operating loss of $755,306 for 1^st quarter fiscal year 2026 as compared to an operating gain of $332,979 for 1^st quarter fiscal year 2025; a net loss of $654,618 for 1^st quarter fiscal year 2026 as compared to a net gain of $392,787 for 1^st quarter fiscal year 2025; and a basic loss per share of $.27 for 1^st quarter fiscal year 2026 as compared to a basic gain per share of $.17 for 1^st quarter fiscal year 2025.

Dave Offerman, President and CEO of IEH Corporation commented, “As forecasted in prior communications, while our long-term trajectory continues to trend upwards, our results from one quarter to the next may be uneven. This is reflected in our first quarter, as revenue was lower than the last few quarters due primarily to customer schedule delays, along with the still slow recovery of the commercial aircraft sector.

However, the long-term projections, especially in our largest sector, defense, remain strong. Indeed, we recently booked over $2.5 million in orders in support of various missile defense programs, including PATRIOT, AMRAAM, LTMADS and others. Our sales pipeline indicates more orders are on the horizon. Our commercial space launch business continues to grow, and we continue to eagerly anticipate a return to pre-COVID levels of business in the commercial aerospace sector. Initiatives to grow our product lines and markets served via organic and inorganic growth continue, and we look forward to sharing more good news in the coming quarters.

On behalf of the management team and staff of IEH, we again wish to express our sincere gratitude for the support of our valued shareholders.”

About IEH Corporation

For over 80 years and 4 generations of family-run management, IEH Corporation has designed, developed, and manufactured printed circuit board (PCB) connectors, custom interconnects and contacts for high performance applications. With its signature Hyperboloid technology, IEH supplies the most durable, reliable connectors for the most demanding environments. The Company markets primarily to companies in defense, aerospace, medical, space and industrial applications, in the United States, Canada, Europe, Southeast and Central Asia and the Mideast. The Company was founded in 1941 and is headquartered in Brooklyn, New York.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Certain statements contained in this press release, and in related comments by the Company’s management, include “forward-looking statements.” All statements, other than statements of historical facts, including, without limitation, statements or expectations regarding our financial condition, statements or expectations regarding our revenues, cash and backlog, expectations regarding future cash requirements, revenue and revenue recovery, including for fiscal year 2026 and beyond, projected timelines for making our SEC filings or successfully preventing our registration from suspension or revocation and expectations regarding our efforts and ability to resolve our inventory accounting issues are forward-looking statements. These statements often include words such as “believe,” “expect,” “estimate,” “plan,” “will,” “may,” “would,” “should,” “could,” or similar expressions, although not all forward-looking statements contain such identifying words. These statements are based on certain assumptions that the Company has made on its current expectations and projections about future events. The Company believes these judgments are reasonable, but you should understand that these statements are not guarantees of performance or results, and you should not place undue reliance on any forward-looking statements. The Company’s actual performance or results could differ materially from those expressed in the forward-looking statements due to a variety of important factors, both positive and negative, as they will depend on many factors about which we are unsure, including many factors beyond our control. Among other items, such factors could include: any claims, investigations or proceedings arising as a result of our past due periodic reports, including changes in the proceedings related to the SEC’s Order Instituting Administrative Proceedings and Notice of Hearing pursuant to Section 12(j) of the Securities and Exchange Act of 1934, as amended; our ability to remediate our inventory accounting issue; our ability to reduce costs or increase revenue; changes in the macroeconomic environment or in the finances of our customers; changes in accounting principles, or their application or interpretation, and our ability to make accurate estimates and the assumptions underlying the estimates; our ability to attract and retain key employees and key resources; and other risk factors discussed from time to time in our filings with the SEC, including those factors discussed under the caption “Risk Factors” in our most recent annual report on Form 10-K, filed with the SEC on June 12, 2025, and in subsequent reports filed with or furnished to the SEC. Additional information concerning these and other factors can be found in our filings with the SEC. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. Except as may be required by applicable law, we do not undertake or intend to update or revise our forward-looking statements, and we assume no obligation to update any forward-looking statements contained in this press release as a result of new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. You should carefully review and consider the various disclosures we make in our filings with the SEC that attempt to advise interested parties of the risks, uncertainties and other factors that may affect our business.

Contact:

Dave Offerman
IEH Corporation
dave@iehcorp.com
718-492-4448

SOURCE: IEH Corp.

View the original press release on ACCESS Newswire

• XCF Global and OpenSponsorship partner to provide sports, entertainment, and music industries with carbon-neutral air travel opportunities

• Initiative drives awareness around reducing aviation emissions by offering a practical carbon offset solution

• Partnership empowers athletes, entertainers, and musicians to leverage their platforms to promote positive societal change

HOUSTON, TEXAS / ACCESS Newswire / August 13, 2025 / XCF Global, Inc. (“XCF”) (Nasdaq:SAFX), a key player in decarbonizing the aviation industry through Synthetic Aviation Fuel (“SAF”) today announces a strategic partnership with OpenSponsorship Corp. (“OpenSponsorship”), a New York-based marketing agency specializing in sponsorships for sports and entertainment industries to drive awareness for carbon-neutral air travel. This campaign creates unique opportunities for sports teams, actors and actresses, and musicians to participate in carbon-neutral travel activities, raising awareness around the decarbonization of air travel.

As part of the partnership, XCF will offer a comprehensive carbon offset solution for sports and entertainment travel, ensuring that flights to games,tournaments, concerts, and other events are fully carbon neutral. Such sponsorships aim to demonstrate a practical and impactful approach to sustainability, contributing to the global movement toward reducing emissions from the aviation industry.

Mihir Dange, CEO and Board Chair of XCF Global commented:

“We are thrilled to partner with OpenSponsorship and bring carbon-neutral travel opportunities to sports, entertainment, and music industries. This partnership enables high-profile individuals and organizations to meaningfully engage with their audiences by showcasing their leadership in sustainability and driving awareness of the need to decarbonize the aviation industry. Together, we’re turning the spotlight on the urgent need to decarbonize the aviation industry and providing a clear path for others to follow.”

OpenSponsorship is revolutionizing the sponsorship landscape by simplifying the connection between brands and talent in the sports, entertainment, and music industries. Their platform provides brands of all industries with streamlined access to the benefits of sports and entertainment sponsorships, empowering them to engage with talent and athletes through mutually beneficial partnerships.

OpenSponsorship Founder and CEO, Ishveen Jolly said:

“We’re excited to work with XCF to bring carbon-neutral travel to the forefront of sports and entertainment sponsorships. Athletes, musicians, and actors hold immense influence, and their global followings make them powerful advocates for change. This partnership empowers them to lead by example, using their platforms to inspire fans and effect positive societal change.”

To explore exciting partnership opportunities or discuss customized sponsorships, reach out to OpenSponsorship at info@opensponsorship.com or visit https://opensponsorship.com/.

About XCF Global, Inc.

XCF Global, Inc. is a pioneering synthetic aviation fuel company dedicated to accelerating the aviation industry’s transition to net-zero emissions. XCF is developing and operating state-of-the-art clean fuel SAF production facilities engineered to the highest levels of compliance, reliability, and quality. The company is actively building partnerships across the energy and transportation sectors to accelerate the adoption of SAF on a global scale. XCF is listed on the Nasdaq Capital Market and trades under the ticker, SAFX. Current outstanding shares: ~149.3 million; 20% free float (as of August 13, 2025).

To learn more, visit www.xcf.global.

Contacts

XCF Global:
C/O Camarco
XCFGlobal@camarco.co.uk

Media:

Camarco
Andrew Archer | Rosie Driscoll | Violet Wilson
XCFGlobal@camarco.co.uk

Forward Looking Statements

This Press Release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. These forward-looking statements, including, without limitation, statements regarding XCF Global’s expectations with respect to future performance and anticipated financial impacts of the recently completed business combination with Focus Impact BH3 Acquisition Company (the “Business Combination”), estimates and forecasts of other financial and performance metrics, and projections of market opportunity and market share, are subject to risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by XCF Global and its management, are inherently uncertain and subject to material change. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) changes in domestic and foreign business, market, financial, political, and legal conditions; (2) unexpected increases in XCF Global’s expenses resulting from potential inflationary pressures and rising interest rates, including manufacturing and operating expenses and interest expenses; (3) the occurrence of any event, change or other circumstances that could give rise to the termination of negotiations and any agreements with regard to XCF Global’s offtake arrangements; (4) the outcome of any legal proceedings that may be instituted against the parties to the Business Combination or others; (5) XCF Global’s ability to meet Nasdaq’s continued listing standards; (6) XCF Global’s ability to integrate the operations of New Rise and implement its business plan on its anticipated timeline; (7) XCF Global’s ability to raise financing in the future and the terms of any such financing; (8) the New Rise Reno production facility’s ability to produce the anticipated quantities of SAF without interruption or material changes to the SAF production process; (9) XCF Global’s ability to resolve current disputes between its New Rise subsidiary and its landlord with respect to the ground lease for the New Rise Reno facility; (10) XCF Global’s ability to resolve current disputes between its New Rise subsidiary and its primary lender with respect to loans outstanding that were used in the development of the New Rise Reno facility; (11) costs related to the Business Combination and the New Rise acquisitions; (12) the risk of disruption to the current plans and operations of XCF Global as a result of the consummation of the Business Combination; (13) XCF Global’s ability to recognize the anticipated benefits of the Business Combination and the New Rise acquisitions, which may be affected by, among other things, competition, the ability of XCF Global to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (14) changes in applicable laws or regulations; (15) risks related to extensive regulation, compliance obligations and rigorous enforcement by federal, state, and non-U.S. governmental authorities; (16) the possibility that XCF Global may be adversely affected by other economic, business, and/or competitive factors; (17) the availability of tax credits and other federal, state or local government support; (18) risks relating to XCF Global’s and New Rise’s key intellectual property rights; (19) the risk that XCF Global’s reporting and compliance obligations as a publicly-traded company divert management resources from business operations; (20) the effects of increased costs associated with operating as a public company; and (21) various factors beyond management’s control, including general economic conditions and other risks, uncertainties and factors set forth in XCF Global’s filings with the Securities and Exchange Commission (“SEC”), including the final proxy statement/prospectus relating to the Business Combination filed with the SEC on February 6, 2025, this Press Release and other filings XCF Global makes with the SEC in the future. If any of the risks actually occur, either alone or in combination with other events or circumstances, or XCF Global’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that XCF Global does not presently know or that it currently believes are not material that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect XCF Global’s expectations, plans or forecasts of future events and views as of the date of this Press Release. These forward-looking statements should not be relied upon as representing XCF Global’s assessments as of any date subsequent to the date of this Press Release. Accordingly, undue reliance should not be placed upon the forward-looking statements. While XCF Global may elect to update these forward-looking statements at some point in the future, XCF Global specifically disclaims any obligation to do so.

SOURCE: XCF Global, Inc.

View the original press release on ACCESS Newswire

RED BANK, NEW JERSEY / ACCESS Newswire / August 13, 2025 / Tharimmune, Inc. (Nasdaq:THAR) (“Tharimmune” or the “Company”), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs, today announced a significant expansion of its intellectual property portfolio for TH-104, its novel transmucosal film. The new patents, recently granted and allowed across key global markets, will enable the Company’s long-term strategy of pursuing broader indications for the technology, beginning with its lead program as a critical medical countermeasure for military and first responders against high-potency opioids.

This announcement follows recent positive feedback from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) pathway for TH-104. The FDA confirmed that a 505(b)(2) NDA submission for the prevention of respiratory and/or central nervous system distress is a viable path, and no additional clinical trials seem to be required for this specific indication for use in military personnel and/or first responders who may be exposed to weaponized high-potency opioids, such as fentanyl or its analogues. This positive feedback, combined with the appointment of counter-terrorism expert James Liddy to the Board of Directors, accelerates the Company’s efforts to position TH-104 as a national security solution.

The recent granting and allowance of patents in Japan, Mexico, Australia, and the United States further strengthen the Company’s intellectual property position, providing protection for TH-104 out to at least 2040 in key markets. While the initial focus is on military and first responders, these patents are foundational for addressing other significant medical needs to combat pruritus, a debilitating form of itch associated with certain chronic liver and kidney diseases.

TH-104 is a buccal film formulation of nalmefene, an opioid antagonist with a significantly longer half-life compared to existing options of autoinjectors and other formulations containing the active ingredient of products such as Narcan^®. This extended duration may provide sustained protection, which is crucial for personnel operating in high-risk environments where repeated dosing may not be feasible.

“The recent patent grants are important for our TH-104 platform,” said Sireesh Appajosyula, CEO of Tharimmune. “This is a dual achievement which validates our innovative drug delivery technology and secures the long-term potential of TH-104 to address multiple high-impact indications. While we are prioritizing its role as a life-saving medical countermeasure for our military and first responders, this patent portfolio provides a runway to develop our lead candidate for other debilitating conditions where there is a significant unmet medical need.”

The newly granted and allowed patents specifically cover a novel method and device for transmucosal administration of nalmefene via a single-layer, self-supporting, mucoadhesive film with distinct domains for optimized drug delivery and pH balance.

The granted and allowed patents include:

• United States (US) Application No. 17/285,971 (Allowed)

• Japan (JP) Patent No. 7603583 (Granted)

• Mexico (MX) Patent No. 422769 (Granted)

• Australia (AU) Patent Application No. 2019361980 (Allowed)

Tharimmune is dedicated to advancing TH-104 to provide a potentially effective and patient-friendly treatment as an option for those in need, beginning with its critical role in national security.

About Tharimmune, Inc.

Tharimmune is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology, inflammation and oncology. Its lead clinical asset, TH104, is being developed for a specific indication via a 505(b)2 pathway for respiratory and/or nervous system depression in military personnel and chemical incident responders who may encounter environments contaminated with high-potency opioids. The expanded pipeline includes other indications for TH104, such as chronic pruritus in primary biliary cholangitis and TH023, a new approach to treating autoimmune diseases along with an early-stage multispecific biologic platform targeting unique epitopes against multiple solid tumors through its proprietary EpiClick^™ Technology. The Company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. Tharimmune continues to position itself as a leader in patient-centered innovation while working to deliver long-term value for shareholders. For more information, visit: www.tharimmune.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding the timing and design of Tharimmune’s future Phase 2 trial, Tharimmune’s strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “depends,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “target,” “should,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Factors that may cause such differences, include, but are not limited to, those discussed under Risk Factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2024 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this release. Subsequent events and developments may cause the Company’s views to change; however, the Company does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this release.

Contacts:

Tharimmune, Inc.
ir@tharimmune.com

SOURCE: Tharimmune Inc.

View the original press release on ACCESS Newswire

Expanded strategic partnership with The Scripps Research Institute to advance proof-of-concept studies and further develop its program combining systemic DNase I with CAR T-cell therapies

Ended the quarter with $4.8 million of cash to fund operations

FRAMINGHAM, MA / ACCESS Newswire / August 13, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the second quarter 2025.

Recent Highlights

• Expanded its collaboration with The Scripps Research Institute (“TSRI”) to advance the development of the Company’s development program evaluating the combination of systemic DNase I and CAR T-cell therapies;

• Announced advancements from its collaboration partner, PeriNess Ltd. (“PeriNess”) including:

  • Entered into a Clinical Study Agreement to support an exploratory clinical study of DNase I in combination with anti-CD19 CAR T cells in patients with large B cell lymphoma;

  • Commenced patient dosing in an exploratory clinical study of systemic DNase I in combination with FOLFIRINOX for the first line treatment of unresectable, locally advanced or metastatic pancreatic cancer at Bnei Zion Medical Center; and

• Continued pursuit of other strategic collaborations to advance the Company’s technology.

“We continue to set a strong foundation that we believe positions us for success as we advance our systemic DNase I in combination with immunotherapy, chemotherapy, and radiotherapy across various oncology indications where there remains significant unmet need. We continue to work with our partners and believe the data and information will be invaluable as we look to realize the full potential of our DNase platform technology. Looking ahead, we remain focused on building momentum across all fronts and driving development toward an IND and Phase 1 clinical trial,” commented James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic.

Xenetic continues to advance its DNase-based technology towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors. Preclinical proof-of-concept studies combining DNase I with chemotherapy, immunotherapies, and CAR-T therapy in hematological and solid tumor and metastatic cancer models have been completed. Building on proof-of-concept success, the program has now advanced to mechanism-of-action and translational studies in preparation for a Phase 1 clinical trial.

Additionally, as previously announced in December 2024, Xenetic entered into a Clinical Trial Services Agreement with PeriNess, under which PeriNess will lead in the regulatory approval, operational execution and management of potential exploratory, investigator initiated studies of recombinant DNase as an adjunctive treatment in patients with pancreatic carcinoma and other locally advanced or metastatic solid tumors receiving chemotherapy and immunotherapy in Israeli medical centers.

Summary of Financial Results for Second Quarter 2025

Net loss for the quarter ended June 30, 2025 was approximately $0.7 million. Research & development expenses for the three months ended June 30, 2025 decreased by approximately $277,000, or 29.7%, to approximately $0.7 million from $0.9 million in the comparable quarter in 2024. General and administrative expenses for the three months ended June 30, 2025 decreased by approximately $472,000, or 41.8%, to approximately $0.7 million from approximately $1.1 million in the comparable quarter in 2024. These decreases were primarily due to certain severance and benefits expensed in connection with separation agreements entered into during the second quarter of 2024 with the Company’s former Chief Executive Officer and Chief Scientific Officer.

The Company ended the quarter with approximately $4.8 million in cash.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company’s DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.

For more information, please visit the Company’s website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” “remain,” “focus”, “confidence in”, “potential”, and other words of similar meaning, including, but not limited to, all statements regarding expectations for our DNase-base oncology platform, including statements regarding: (a) advancing our DNase-based oncology program towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors and our focus on building momentum and driving development toward an IND and Phase I clinical trial, (b) setting a strong foundation that we believe positions us for success as we advance DNase I in combination with various types of therapy and (c) working with our partners and our belief regarding the data and information as we look to realize the full potential of DNase. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements; (2) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (3) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (4) failure to realize the anticipated potential of the DNase or PolyXen technologies; (5) the ability of the Company to obtain funding and implement its business strategy; and (6) other risk factors as detailed from time to time in the Company’s reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues, and geopolitical events, such as the conflicts in Ukraine and in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation, and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.

Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
xbio@jtcir.com

SOURCE: Xenetic Biosciences, Inc.

View the original press release on ACCESS Newswire

Industry experts warn that payroll mistakes are becoming a leading cause of tax penalties for small business owners in 2025.

IRVINE, CALIFORNIA / ACCESS Newswire / August 13, 2025 / A growing number of small business owners are facing costly penalties from the Internal Revenue Service (IRS) due to payroll errors, according to recent industry data. With changing regulations, new digital filing requirements, and heightened IRS enforcement, experts say payroll missteps are more than just bookkeeping blunders – they can become expensive liabilities.

“Payroll isn’t just about paying employees on time – it’s about paying the right taxes, to the right agencies, at the right time,” said a spokesperson for Clear Start Tax, a national tax relief and resolution firm. “We’re seeing an uptick in IRS penalties for businesses that underreport, misclassify employees, or miss deposit deadlines, and the financial fallout can be devastating.”

Common mistakes include misclassifying workers as independent contractors instead of employees, failing to deposit withheld taxes promptly, and overlooking quarterly filing requirements. These errors can lead to penalties, interest charges, and in some cases, IRS liens or levies.

Clear Start Tax warns that the IRS has increased its use of automated systems to flag payroll inconsistencies.

“Business owners need to understand that payroll taxes are one of the IRS’s top collection priorities,” the spokesperson added. “Once a payroll issue is identified, the clock starts ticking, and penalties can snowball quickly.”

To help business owners stay compliant, Clear Start Tax recommends:

• Double-checking worker classification to ensure IRS guidelines are met.

• Scheduling automated tax deposits to avoid missed deadlines.

• Reconciling payroll reports with tax filings each quarter.

• Consulting a tax professional before making major payroll changes.

By answering a few simple questions, taxpayers can find out if they’re eligible for the IRS Fresh Start Program and take the first step toward resolving their tax debt.

“Proactive compliance is the best defense,” said the spokesperson. “A small oversight today can turn into a major problem six months from now. The businesses that survive and thrive are the ones that get ahead of these issues before the IRS gets involved.”

About Clear Start Tax
Clear Start Tax is a nationwide tax resolution and relief firm specializing in helping individuals and businesses address IRS and state tax issues. With a team of experienced tax professionals, the company provides tailored strategies for resolving back taxes, negotiating settlements, and achieving long-term compliance.

Need Help With Back Taxes?

Click the link below:
https://clearstarttax.com/qualifytoday/
(888) 710-3533

Contact Information

Clear Start Tax
Corporate Communications Department
tech@clearstarttax.com
(949) 800-4011

SOURCE: Clear Start Tax

View the original press release on ACCESS Newswire

CASCAIS, PORTUGAL / ACCESS Newswire / August 13, 2025 / Pulsar Helium Inc. (AIM:PLSR)(TSXV:PLSR)(OTCQB:PSRHF) (“Pulsar” or the “Company“), a leading helium project development company, is pleased to announce that it has engaged London, U.K. based Yellow Jersey PR Limited (“Yellow Jersey“) as a consultant to carry out investor and public relations services and activities for a monthly fee of £3,500, for a twelve-month term commencing on August 12, 2025, with the first five months being a fixed term. Such services and activities include advising the Company on all aspects of its communications with the investment community and the media; co-advising on the form and content of announcements and press releases; releasing announcements required by the AIM Rules for Companies to a Regulatory Information Service on behalf of the Company; managing the Company’s social media; and arranging meetings between the Company and analysts, journalists, existing and potential investors.

The Company’s agreement with Yellow Jersey can be terminated by either party giving two months’ notice in writing, following the completion of the first five-month fixed term. Yellow Jersey has advised the Company that it does not currently hold any common shares in the Company; as such, Yellow Jersey and the Company are unrelated and unaffiliated entities.

On behalf Pulsar Helium Inc.

“Thomas Abraham-James”
President, CEO and Director

Further Information:
Pulsar Helium Inc.
connect@pulsarhelium.com
+ 1 (218) 203-5301 (USA/Canada)
+44 (0) 2033 55 9889 (United Kingdom)
https://pulsarhelium.com
https://ca.linkedin.com/company/pulsar-helium-inc.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Pulsar Helium Inc.

View the original press release on ACCESS Newswire

Med spas together with hospital systems have started compressing private practices; Dr. Meegan Gruber urges patients to prioritize safety.

TAMPA, FLORIDA / ACCESS Newswire / August 13, 2025 / Board-Certified Plastic Surgeon Dr. Meegan Gruber, MD, PhD, has launched an alert about the fast transformation of private practice ownership from physicians to large hospital systems and fast-growing med spas. The AMA conducted a benchmark survey which revealed that private practice physicians decreased from 60.1% in 2012 to 42.2% in 2024. Patients require ongoing medical care with personal physician supervision. The current market dynamics override medical expertise when it comes to determining both the delivery sites and methods of aesthetic care, according to Dr. Gruber.

The medical landscape has transformed into a hospital and corporate employment-based structure — a national analysis by the Physicians Advocacy Institute and Avalere found hospital and corporate employment rates reached 77.6% by January 2024. The same study indicates hospital employment increased to 55.1% while corporate employment reached 22.5% because of intense consolidation, which weakens patient-physician decision-making.

Med spas have both proliferated in numbers and generated substantial revenue growth during the same period. Medical spas in the United States now operate above $17 billion annually while their market grows at a rate exceeding $1 billion yearly, according to the American Med Spa Association. The American Med Spa Association reports that the medical spa industry now generates $17 billion in revenue annually and adds $1 billion each year to its market value. New medical spa establishments increased by 18% during 2023, according to recent data. Medical standards that lack uniformity will produce inconsistent treatment results according to Dr. Gruber. Multiple states experienced hospitalizations because federal investigations revealed multiple cases of counterfeit botulinum toxin and mishandled injections in non-regulated medical settings.

Price and convenience will never replace the importance of medical training and established protocols, according to Dr. Gruber. Patients should verify the identity of the procedure performer and the supervising physician’s board certification and confirm emergency readiness at the facility. She suggests patients check for ABMS-recognized board certification in plastic surgery and insist on meeting the surgeon personally and verify where they source injectables.

Dr. Gruber provides awake surgery under local anesthesia to qualified candidates as an option that reduces general anesthesia exposure and enables real-time team communication. She stated that the patient needs to be the correct choice while the procedure needs to be appropriate for the patient and the treatment must occur in an appropriate environment.

At Gruber Plastic Surgery patients can discover more information about physician-led care that maintains continuity and learn about awake surgery and schedule a safety oriented consultation by contacting us.

About Gruber Plastic Surgery

Gruber Plastic Surgery, located in Tampa, FL, is led by Dr. Meegan Gruber, Ph.D., board-certified plastic surgeon renowned for her pioneering work in awake plastic surgery. Dr. Gruber, also the star of “Awake Surgery,” which you can stream today on TLC GO, HBO MAX, Hulu, Discovery+, and other streaming platforms, integrates advanced techniques and cutting-edge technology to deliver safe, comfortable, and natural-looking results with minimized recovery time. Specializing in awake surgeries, the clinic offers a range of state-of-the-art procedures. Dr. Gruber is committed to innovation and education, ensuring precision and safety in every treatment, while enhancing patient confidence through individualized care and surgical expertise.

Contact Information

Jay Saint
info@drmeegangruber.com
888-400-0086

SOURCE: Gruber Plastic Surgery

Related Images

View the original press release on ACCESS Newswire

Dispatch continues to scale last-mile logistics through strategic investments in AI, talent, and customer success.

BLOOMINGTON, MN / ACCESS Newswire / August 13, 2025 / Dispatch is proud to announce its inclusion on the 2025 Inc. 5000 list of America’s fastest-growing private companies for the fourth consecutive year. This prestigious recognition highlights Dispatch’s sustained growth and technological innovation within the highly competitive logistics and transportation sector.

“Being named to the Inc. 5000 once again is an incredible achievement and speaks to our ongoing commitment to scaling last-mile delivery for businesses of all sizes,” said Andrew Leone, CEO and Co-Founder of Dispatch. “This recognition reflects the hard work our team has invested in expanding our capabilities, particularly in areas like AI, company culture, and customer retention. As the industry continues to evolve, we remain focused on driving impactful change in the logistics space.”

Key Growth Drivers

Over the past year, Dispatch has experienced significant growth, driven by strategic investments in technology, talent, and customer success. The company has expanded its AI-driven solutions, enabling an efficient and scalable last-mile delivery platform for businesses across various industries. Dispatch has also strengthened its team, focusing on fostering a positive culture and promoting internal talent, which has been critical to maintaining operational excellence. As a result, Dispatch has seen a remarkable increase in both its customer base and revenue, with a 68% three-year growth rate.

Inc. Methodology

Companies on the 2025 Inc. 5000 are ranked according to percentage revenue growth from 2021 to 2024. To qualify, companies must have been founded and generating revenue by March 31, 2021. They must be U.S.-based, privately held, for-profit, and independent – not subsidiaries or divisions of other companies – as of December 31, 2024. (Since then, some on the list may have gone public or been acquired.) The minimum revenue required for 2021 is $100,000; the minimum for 2024 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons.

For the full Inc. 5000 list, visit: www.inc.com/inc5000.

About Inc.: Inc. is the leading media brand and playbook for the entrepreneurs and business leaders shaping our future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of its community: the risk-takers, the innovators, and the

ultra-driven go-getters who are creating the future of business. Inc. is published by Mansueto Ventures LLC, along with fellow leading business publication Fast Company. For more information, visit www.inc.com.

About Dispatch: Dispatch is redefining last-mile delivery for the modern business. As the premier B2B delivery platform, Dispatch empowers organizations with scalable, technology-driven solutions that streamline logistics, enhance visibility, and improve customer satisfaction. Through its robust delivery management software, seamless API integrations, and a reliable network of independent contractor drivers, Dispatch enables businesses of all sizes to simplify and optimize their last-mile operations.

Media Contact:

For more information about Dispatch, please contact the media representative at:

Email: pr@dispatchit.com
Website: www.dispatchit.com

SOURCE: Dispatch

Related Images

View the original press release on ACCESS Newswire

• BUZZ BOMB™ is bringing its unique delivery technology benefits to the multi-billion-dollar pre-workout to help athletes and fitness enthusiasts maximize their performance potential

• 30,000 BUZZ BOMB™ sample packs of four 50mg stick packs in each flavor distributed to convention attendees

• Well-known fitness instructors, fitness celebrities, athletes, and influencers along with thousands of fitness enthusiasts and consumers sampled BUZZ BOMB™’s four bold flavors

• As part of its launch, Aspire plans on partnering with well-known athletes and influencers across fitness training and endurance sports to accelerate consumer awareness and uptake

• BUZZ BOMB™ is available for purchase at buzzbomb.buzz, the Company’s new E-commerce website

ESTERO, FL / ACCESS Newswire / August 13, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), developer of a multi-faceted patent-pending supplement delivery technology, today announced the successful launch and distribution of over 30,000 BUZZ BOMB™ sample four-packs, its newsublingual pre-workout supplement, at FitCon and FitExpo, held August 1-3, in Salt Lake City and Anaheim, with an estimated combined attendance in excess of 70,000 people.

BUZZ BOMB™, featuring 50mg of caffeine and offered in four flavors (Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha), provides nearly instant energy, in easy-to-use small sublingual packets, which can be taken right before and during work out as needed. Unlike most pre-workout products that are mixed with water and taken well before a workout, BUZZ BOMB™ is sprinkled under the tongue right before or during a workout for immediate effect via direct delivery to the bloodstream.

BUZZ BOMB™ FitExpo Launch

Click here for BUZZ BOMB FitExpo Convention August 2-3, 2025 Video

BUZZ BOMB™ Testimonial from Leading Figures in the Fitness World

Bobby Maximus is a UFC fighter, Ju Jitsu Masters World Champion and fitness trainer. He has broken multiple power-endurance world records and is recognized as a leading figure in the fitness world. He starred in the recent feature film “Kill Shot” and is a best-selling Men’s Health author and a regular contributor to “Men’s Health” magazine (https://www.menshealth.com/author/214988/bobby-maximus/).

“In just about a minute, it feels like I drank a pre-workout 20 minutes ago.”

“The taste… phenomenal! I really like that.”

“I work out 2-3 times a day. One of the most inconvenient things is trying to time your pre workout drink 30 minutes before your workout. “

When I have a short window, I don’t want to wait 30 minutes until it kicks in. The ability to just ‘dump and go’ with Buzz Bomb, is powerful. It’s the convenience factor!

“I love the idea behind it! It helps me keep my caffeine intake down. Especially when you train 2 to 3 times a day.”

“You cannot find another pre work with 50 mgs of caffeine… and it works! I love it!”

Brandon “MidWest Kong” Copeland (pictured above, third to the right) embodies the strength of a champion and the heart of a hero. A Brazilian Jiu-jitsu Black Belt, Copeland dominated the Mixed Martial Arts scene from 2005 to 2014, showcasing tenacity and skill. Initiating the “I Stopped The Bully” campaign in 2011, he became a beacon against bullying, inspiring youth across schools and detention centers. Copeland excelled in the fitness industry, breaking records like bench pressing 225 pounds 81 consecutive times. A published children’s book author, he spreads messages of hope and community.

“I took the product! Let me say thank God! No heart flutter, no itchy sensation, no crash! I don’t need the hard stuff anymore…feels absolutely great! I had a great workout as well!”

Commenting on the BUZZ BOMB™ launch, Kraig Higginson, Interim Chief Executive Officer of Aspire, said, “The launch and consumer response to BUZZ BOMB™ at two of the major fitness conventions, from booth activity, product sampling, feedback, interest from fitness experts and influencers, and potential licensing partners, exceeded all of our high expectations.”

Higginson added, “With BUZZ BOMB™, we’re raising the bar for ease of use, performance and value in the multi-billion-dollar caffeine category. We focused on creating a formula that is fast-absorbing and built for athletes, fitness enthusiasts and consumers who demand clean, effective fuel without unnecessary fillers or compromise. With online sales commencing August 1, we are now focused on increasing our marketing, expanding our third-party manufacturing capabilities, and preparing for further discussions with potential licensing partners in the nutritional and supplement space that can help us drive increased consumer awareness and accelerate our revenue potential for BUZZ BOMB™.”

Consumers can purchase BUZZ BOMB™ online at buzzbomb.buzz

BUZZ BOMB™ Pre-workout Benefits:

• Speed – works nearly immediately (less than 2 minutes) vs. 20-30 minutes

• Convenience – easy to use single-use packets vs. mixing and measuring for beverages

• Energy management – use as needed to precisely manage caffeine intake (50mg increments)

• Single Safe Active Ingredient – well-known benefits and use of caffeine

• A clean manageable Energy Boost

• Low manufacturing & packaging costs – competitive pricing with high margin potential

Aspire’s BUZZ BOMB™ – Sublingual nano technology delivers 50mg of caffeine rapidly to the body, bringing its unique benefits to the pre-workout market.

About Aspire Biopharma, Inc.

Headquartered in Estero, Fl., Aspire Biopharma has developed a patent-pending disruptive technology that can deliver supplements and drugs to the body rapidly and precisely with less negative impact to the system by going directly to the bloodstream and avoiding the gastrointestinal tract. For more information, please visit www.aspirebiolabs.com.

Safe Harbor Statement

Certain statements made in this communication are “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as “estimate,” “projects,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “would,” “should,” “future,” “propose,” “potential,” “target,” “goal,” “objective,” “outlook” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Aspire’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Aspire Biopharma Holdings, Inc.

Contact

PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

Rene Veloso, JD, MBA, joins KIFFIK to lead investor relations and secure new funding to fuel clinical operations

Rubix Life Sciences CEO Reginald Swift, Ph.D. joins as Chief Scientific Officer with responsibility to shape KIFFIK’s clinical strategy

PROVIDENCE, RI / ACCESS Newswire / August 13, 2025 / KIFFIK Biomedical, Inc. (“Kiffik”), a leader in interstitial fluid (ISF)-based diagnostics, today announced two new appointments to its leadership team. Healthcare development executive Rene Veloso joins as Chief Investment Officer (CIO) along with Dr. Reginald(Reggie) Swift who will serve as a fractional Chief Scientific Officer (CSO).

“The addition of Rene and Reggie to our already strong leadership team is a game-changer as we embark on our next chapter of growth,” said George Cagna, CEO of KIFFIK Biomedical. “Ensuring our R&D function is meeting the highest scientific standards, coupled with securing operating capital, empowers our team to bring next-generation ISF biomonitoring to partners and patients.”

As CIO, Rene will be responsible for securing capital investments from institutional partners that want to unlock the full potential of interstitial fluid real-time monitoring for a range of cancers and other diseases. Most recently, Rene was Senior Vice President at Locust Walk Partners, LLC where he led multiple high-profile M&A activities on behalf of biopharma clients.

Dr. Reginald Swift is the CEO of Rubix Life Sciences, a leader in aptamer-based precision medicine. As a fractional CSO for KIFFIK Dr. Swift will help shape clinical operations to ensure research and development activities meet the highest scientific standards. Earlier this year, KIFFIK and Rubix LS established a strategic partnership to advance next-generation ISF extraction technology.

About KIFFIK Biomedical

KIFFIK Biomedical is pioneering interstitial fluid (ISF)-based diagnostics, transforming disease detection and health monitoring with a needle-free, real-time approach. As a leader in ISF science and biomarker detection, we are redefining non-invasive diagnostics for oncology, therapeutic monitoring, and beyond.

Our proprietary and patented KIFFIK EXP platform unlocks the potential of ISF, providing high-precision, accessible, and patient-friendly solutions. Through strategic partnerships and cutting-edge research, KIFFIK is driving the future of precision medicine and advancing diagnostics that empower earlier detection and better health outcomes.

###

Media Contact

MDL Strategic Communications
Michael Lauer
michael@mdlcomms.com

SOURCE: Kiffik

View the original press release on ACCESS Newswire